Items where Funder is Actuate Therapeutics, Inc.

No Ext Ref

Shaw, G., Cavalcante, L., Giles, F.J. et al. (1 more author) (2022) Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8+ T cell cytolytic killing of melanoma cells. Journal of Hematology & Oncology, 15. 134. ISSN 1756-8722